Epidemiology, Healthcare Resource Utilization, and Costs of Unresectable Locally Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma in China
Author(s)
yang chen, MD, PhD1, Yi Xie, MD, PhD1, Lei Jiang, MD, PhD1, Haoxin Peng, MD, PhD1, Dan Liu, MD, PhD1, Jiajia Yuan, MD, PhD1, Xiaotian Zhang, MD, PhD1, Mok Oh, PharmD, PhD2, Yongji Lu, MS3, Lu Ban, PhD4, Lin Shen, MD1.
1Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China, 2Astellas Pharma, Inc., Northbrook, IL, USA, 3Astellas China Investment Co., Beijing, China, 4Evidera, Beijing, China.
1Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China, 2Astellas Pharma, Inc., Northbrook, IL, USA, 3Astellas China Investment Co., Beijing, China, 4Evidera, Beijing, China.
Presentation Documents
OBJECTIVES: Gastric cancer is the fifth most common cancer and third leading cause of cancer-related death in China. This observational, descriptive study aimed to understand the epidemiology, healthcare resource utilization (HCRU), and costs of unresectable locally advanced or metastatic (la/m) gastric adenocarcinoma (Ga) and gastroesophageal junction adenocarcinoma (GEJa) in China.
METHODS: Electronic medical records (National Cancer Center Oncology Information Database) of adults with unresectable la/m Ga and GEJa (diagnosed January 2016 to June 2022) were used. HCRU and costs were assessed from first diagnosis of la/m Ga or GEJa until the earliest of last inpatient, emergency, or outpatient visit; other primary cancer occurrence; clinical trial participation; or December 2022.
RESULTS: From 2016 to 2022, 64,807 and 18,412 patients were diagnosed with Ga and GEJa, respectively; 22,156 and 6183 patients met study inclusion criteria. Mean (SD) age (years) at diagnosis was 59.0 (12.3) for la/m Ga and 64.5 (10.1) for la/m GEJa; 14,837 (67.0%) and 5125 (82.9%) patients were male. Among la/m Ga patients, 17,061 (77.0%) had a Ga-related inpatient admission (0.31 [95% CI: 0.31, 0.31] per patient-month [PPM]; cumulative incidence at 12-month follow-up: 78.3%) and 9526 (43.0%) had a Ga-related outpatient visit (0.28 [0.27, 0.28] PPM; cumulative incidence: 49.3%). Among la/m GEJa patients, 4818 (77.9%) had a GEJa-related inpatient admission (0.28 [0.28, 0.29] PPM; cumulative incidence: 77.9%) and 1428 (23.1%) had a GEJa-related outpatient visit (0.13 [0.13, 0.13] PPM; cumulative incidence: 27.1%). Mean (SD) costs (US dollars [December 2022 exchange rate]) PPM of Ga-related and GEJa-related treatment were: inpatient admissions, $2100.81 ($4452.05) and $1891.51 ($4346.76); outpatient visits, $165.74 ($375.44) and $140.11 ($310.33); EOX chemotherapy, $139.35 ($397.06) and $137.38 ($426.00); FOLFOX chemotherapy, $141.88 ($402.86) and $148.31 ($518.65); and CAPOX chemotherapy, $139.62 ($398.19) and $137.06 ($426.47).
CONCLUSIONS: Unresectable la/m Ga and GEJa are associated with significant HCRU and costs in China.
METHODS: Electronic medical records (National Cancer Center Oncology Information Database) of adults with unresectable la/m Ga and GEJa (diagnosed January 2016 to June 2022) were used. HCRU and costs were assessed from first diagnosis of la/m Ga or GEJa until the earliest of last inpatient, emergency, or outpatient visit; other primary cancer occurrence; clinical trial participation; or December 2022.
RESULTS: From 2016 to 2022, 64,807 and 18,412 patients were diagnosed with Ga and GEJa, respectively; 22,156 and 6183 patients met study inclusion criteria. Mean (SD) age (years) at diagnosis was 59.0 (12.3) for la/m Ga and 64.5 (10.1) for la/m GEJa; 14,837 (67.0%) and 5125 (82.9%) patients were male. Among la/m Ga patients, 17,061 (77.0%) had a Ga-related inpatient admission (0.31 [95% CI: 0.31, 0.31] per patient-month [PPM]; cumulative incidence at 12-month follow-up: 78.3%) and 9526 (43.0%) had a Ga-related outpatient visit (0.28 [0.27, 0.28] PPM; cumulative incidence: 49.3%). Among la/m GEJa patients, 4818 (77.9%) had a GEJa-related inpatient admission (0.28 [0.28, 0.29] PPM; cumulative incidence: 77.9%) and 1428 (23.1%) had a GEJa-related outpatient visit (0.13 [0.13, 0.13] PPM; cumulative incidence: 27.1%). Mean (SD) costs (US dollars [December 2022 exchange rate]) PPM of Ga-related and GEJa-related treatment were: inpatient admissions, $2100.81 ($4452.05) and $1891.51 ($4346.76); outpatient visits, $165.74 ($375.44) and $140.11 ($310.33); EOX chemotherapy, $139.35 ($397.06) and $137.38 ($426.00); FOLFOX chemotherapy, $141.88 ($402.86) and $148.31 ($518.65); and CAPOX chemotherapy, $139.62 ($398.19) and $137.06 ($426.47).
CONCLUSIONS: Unresectable la/m Ga and GEJa are associated with significant HCRU and costs in China.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE313
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Gastrointestinal Disorders, SDC: Oncology